…and pathophysiology Low density lipoprotein cholesterol (LDL C) is the principal therapeutic target in lipid management because LDL and other apolipoprotein B containing lipoproteins play…

…of low density lipoprotein receptors (LDLRs), which enhances removal of circulating LDL particles. Its principal clinical effect is therefore reduction of LDL cholesterol (LDL C…

…Very low density lipoprotein (VLDL) Chylomicrons and other triglyceride rich particles Thus, non HDL C provides a broader estimate of atherogenic cholesterol than LDL C…

…lowering agent used to reduce low density lipoprotein cholesterol (LDL C), particularly when statins cannot be tolerated or when LDL C remains above goal despite…

…FH) is an inherited disorder characterized by persistently elevated plasma low density lipoprotein cholesterol (LDL C) from early life and a consequent excess risk of…

…Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a hepatic protein that regulates the availability of the low density lipoprotein receptor (LDL receptor) on hepatocytes…

…the availability of hepatic low density lipoprotein cholesterol (LDL C) receptors at the cell surface, and thereby enhances removal of LDL C from the circulation…

…and acute coronary syndromes (ACS). Its principal therapeutic objective is reduction of low density lipoprotein cholesterol (LDL C), the primary lipid target in contemporary secondary…

…apolipoprotein B (ApoB) containing lipoproteins, predominantly low density lipoprotein cholesterol (LDL C) [3] . Once trapped within the subendothelial space, LDL C particles undergo oxidative modification…

…promote insulin resistance, free fatty acid synthesis and very low density lipoprotein production. Cyclosporine raises LDL cholesterol, partly by reducing LDL receptor availability. Tacrolimus appears…